Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
17.6% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
20
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.1% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
17
users have liked this narrative
7
users have commented on this narrative
23
users have followed this narrative
9 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
4.7% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
20
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Harmony Biosciences Holdings
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
WAKIX Reliance Will Invite Patent Expiry And Pricing Woes
Key Takeaways Over-reliance on a single key product exposes the company to concentration risk and vulnerability when patent protections expire or rivals enter the market. Evolving payer, regulatory, and scientific landscapes threaten pricing power, future earnings visibility, and long-term demand for the company's portfolio.
View narrative
US$31.00
FV
18.2% overvalued
intrinsic discount
13.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 12 hours ago
author updated this narrative
Verint Systems
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Competitive Risks Will Undermine AI Promise Though Gains Will Emerge
Key Takeaways Competitive pressure from tech giants and startups, plus stricter data regulations, threaten Verint's growth, pricing power, and scalability of its analytics platform. High R&D spending and long sales cycles could limit margin expansion, create adoption risks, and increase customer churn if AI results disappoint.
View narrative
US$23.00
FV
18.3% undervalued
intrinsic discount
5.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Ibotta
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Rising Privacy Regulations Will Crush Digital Ad Prospects
Key Takeaways Intensifying regulatory pressures and shifting brand loyalty trends threaten Ibotta's advertiser base, constraining revenue growth and margin improvement. Rising competition from retailer programs and high technology spend limit Ibotta's ability to improve earnings, with organizational upheaval heightening sales and client retention risks.
View narrative
US$24.00
FV
14.4% overvalued
intrinsic discount
-2.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Adient
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Rising Regulatory Costs Will Erode Margins Despite US Wins
Key Takeaways Shifting industry trends and regulatory pressures threaten Adient's core market while increasing costs and dampening revenue growth prospects. Industry consolidation and OEMs' move to in-house production weaken Adient's bargaining power and customer base, pressuring margins and profitability.
View narrative
US$17.00
FV
36.0% overvalued
intrinsic discount
0.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Tronox Holdings
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Compliance Costs And Fierce Chinese Competition Will Hamper Margins
Key Takeaways Increasing regulatory and environmental pressures, along with sustained demand shifts, threaten long-term profitability and revenue stability for Tronox. High debt levels and exposure to industry overcapacity amplify financial risks, constraining future growth and flexibility.
View narrative
US$1.11
FV
240.1% overvalued
intrinsic discount
-0.013%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Mankind Pharma
AN
AnalystHighTarget
Consensus Narrative from 17 Analysts
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
Key Takeaways Strong specialty biologics portfolio, innovative pipeline, and rapid execution position the company for accelerated margin and earnings growth ahead of consensus expectations. Expanding distribution, premium consumer brands, and robust R&D create a structural edge to capitalize on rising healthcare demand and chronic disease prevalence.
View narrative
₹3.30k
FV
24.0% undervalued
intrinsic discount
16.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Aspen Aerogels
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Rising Regulation And Capital Strains Will Weaken EV Outlook
Key Takeaways Revenue growth and profitability are threatened by regulatory uncertainty, reduced demand in core markets, and rising compliance and input costs. Sustained cash flow pressures and intensifying competition create risks of margin compression, asset dependency, and diminished market diversification.
View narrative
US$6.00
FV
11.3% overvalued
intrinsic discount
0.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Edgewell Personal Care
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Legacy Brand Erosion Will Pressure Margins Despite Isolated Gains
Key Takeaways Shifting consumer preferences and rising competition threaten core brands and margins, increasing pressure on Edgewell's innovation, pricing, and market positioning. Operational cost pressures, restructuring challenges, and weak non-core innovation undermine profit growth, financial flexibility, and shareholder returns.
View narrative
US$21.00
FV
11.3% overvalued
intrinsic discount
1.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 12 hours ago
author updated this narrative
Cheesecake Factory
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Overvaluation And Rising Costs Will Threaten Dine-In Traffic
Key Takeaways Persistent cost pressures and shifting consumer preferences threaten profitability and necessitate costly menu innovation to maintain brand relevance. Limited expansion capability and increased competition from more adaptable concepts restrain growth and earnings potential.
View narrative
US$50.41
FV
22.8% overvalued
intrinsic discount
5.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 12 hours ago
author updated this narrative
Value any company in seconds
Popular companies